Release topline data from Phase 3 clinical trial of F351 in CHB-associated liver fibrosis
Delivered after the deadline (52 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 6 Jan 2025
- Due
- 31 Mar 2025
- Delivered
- 22 May 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by early 2025”
What we found
Evidence strength B What the grades mean
Gyre guided topline data 'by early 2025' but revised timing to Q2 2025 and actually reported results on May 22, 2025, after the original deadline.
-
B Gyre Therapeutics' Hydronidone Met the Primary Endpoint... Company press release announcing Phase 3 topline results
-
D Gyre Therapeutics Announces Publication of Protocol... Company revises expected readout to Q2 2025, after original deadline
-
D Gyre Therapeutics Announces Alignment with China's CDE... Confirms topline results were disclosed on May 22, 2025
-
D Gyre Therapeutics' Hydronidone Met the Primary Endpoint... Investor relations copy confirming May 22, 2025 announcement
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Release
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Gyre Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-GYRE-000049 · Corrections policy